Inactive Instrument

Amyris, Inc.

AMRS

US03236M2008

Amyris, Inc. Provides Revenue Guidance for the Full Year 2023

March 15, 2023 at 04:11 pm EDT

Amyris, Inc. provided revenue guidance for the full year 2023. Total revenue (Core revenue plus strategic transaction) is expected to grow 95-100% for full year 2023 compared to 2022.

Latest news about Amyris, Inc.

Han Kieftenbeld to leave as Chief Financial Officer of Amyris, Inc	May. 07	CI
Kathy L. Fortmann to Join Amyris, Inc. as Member of the Board of Directors	May. 07	CI
Amyris, Inc. Announces Chief Executive Officer Changes	May. 07	CI
Amyris, Inc. Emerged from Bankruptcy	May. 07	CI
North American Morning Briefing : Stock Futures -2-	Mar. 13	DJ
Third Amended Joint Reorganization Plan Approved for Amyris, Inc.	Feb. 06	CI
Third Amended Joint Reorganization Plan Filed by Amyris, Inc.	Jan. 22	CI
Notice for Auction Cancellation Filed by Amyris, Inc.	Jan. 16	CI
Foris Ventures Provides Information to the Shareholders	Jan. 05	CI
Advance Auto Parts Names Elizabeth Dreyer as Chief Accounting Officer	Jan. 05	MT
First Motion for Exclusivity Period Extension Approved For Amyris, Inc.	Jan. 04	CI
Amyris, Inc., Amyris Clean Beauty, Inc., and Aprinnova, LLC Enter into Amendment to That Certain Senior Secured Super Priority Debtor in Possession Loan Agreement	Jan. 04	CI
Motion for Asset Sale Approved for Amyris, Inc.	Jan. 03	CI
Dr. Reddy's Laboratories Acquires MenoLabs Business	Jan. 03	MT
Mounting Geopolitical Tensions Weigh Down Indian Equities on Wednesday	Jan. 03	MT
Dr. Reddy's Acquires Women's Health and Diery Supplements Brand MenoLabs	Jan. 03	MT
Amyris, Inc. cancelled the transaction announced on December 29, 2022	Dec. 28	CI
Amyris, Inc. Announces Resignation of Elizabeth Dreyer as Chief Accounting Officer and Corporate Controller, Effective as of January 2, 2024	Dec. 27	CI
Motion for Asset Sale Approved for Amyris, Inc.	Dec. 20	CI
Motion for Asset Sale Approved for Amyris, Inc.	Dec. 20	CI
Motion for Asset Sale Approved for Amyris, Inc.	Dec. 20	CI
Bidding Procedure Approved for Amyris, Inc.	Dec. 19	CI
Motion for Asset Sale Filed by Amyris, Inc.	Dec. 14	CI
Notice of Selection of Successful Bidder by Amyris, Inc.	Dec. 13	CI
Motion for Asset Sale Approved for Amyris, Inc.	Dec. 11	CI

Amyris, Inc. is a synthetic biotechnology company. The component of the Company is derived from marketing and selling Clean Beauty, Personal Care, and Health & Wellness consumer products through its direct-to-consumer e-commerce platforms and a growing network of retail partners. The Companyâs sustainable ingredients are sold in bulk to industrial leaders who serve Flavor & Fragrance (F&F), Nutrition, Food & Beverage, and Clean Beauty & Personal Care end markets. The ingredients and consumer products it produces by its Lab-to-Market technology platform. The Company leverages machine learning, robotics, and artificial intelligence, which enables its technology platform to rapidly bring new market at commercial scale. The Lab-to-Market technology platform utilizes optimized and automated molecular biology, analytical, and process development tools combined with machine learning algorithms and statistical models to transform the way microbes metabolize sugars.

Sector

Specialty Chemicals

More about the company

Sector Other Specialty Chemicals

	1st Jan change	Capi.
ECOLAB INC.	+19.99%	67.97B
SIKA AG	-6.03%	45.92B
GIVAUDAN SA	+22.27%	43.74B
FUJIFILM HOLDINGS CORPORATION	+33.20%	28.16B
EMS-CHEMIE HOLDING AG	+8.15%	19.17B
SYMRISE AG	+14.71%	17.12B
CELANESE CORPORATION	-13.18%	14.73B
POSCO FUTURE M CO., LTD.	-27.99%	14.52B
SOCIEDAD QUÍMICA Y MINERA DE CHILE S.A.	-32.33%	11.64B

Other Specialty Chemicals